జర్నల్ ఆఫ్ స్టెమ్ సెల్ రీసెర్చ్ & థెరపీ

నైరూప్య

Targeting Stem Cell Protein BMI1; A Potential Therapeutic Approach for Prostate Cancer Therapy

Firdous H Beigh, Nidda Syeed, Mohsin Maqbool and Rita Singh Majumdhar

Prostate cancer (CaP) is considered as a vexing challenge for clinical management because of its resistance to the conventional therapies, resulting in most deaths from this disease. The current treatment options including castration shows minimal effect, as most of the patients develop resistance and relapse of more aggressive Castration Resistant Prostate Cancer (CRPC). BMI1 (B cell-specific Moloney murine leukemia virus integration site 1), an oncogenic member of the polycomb group gene family and a transcriptional repressor has emerged as a key regulator in numerous processes including proliferation, differentiation, senescence, and stem cell renewal. Accumulating evidences have also revealed a relationship between BMI1 expression and the clinical grade/stage, therapy response, and survival outcome in most human malignancies, including Prostate cancer. Therefore, in this review, we provide the significant evidences suggesting the potential of BMI1 as a therapeutic target in the management of prostate cancer.